Sven-Erik Olofsson 1 , Torgrim Tandstad , Mats Jerkeman , Olav Dahl , Olof Ståhl , Olbjørn Klepp , Roy M Bremnes , Gabriella Cohn-Cedermark , Carl W Langberg , Anna Laurell , Arne Solberg , Ulrika Stierner , Rolf Wahlqvist , Hans Wijkström , Harald Anderson , Eva Cavallin-Ståhl
May 20 2011
From 1995 to 2003, 603 adult patients from Sweden and Norway with metastatic testicular nonseminomatous germ cell tumor (NSGCT) were included prospectively in a population-based protocol with strict guidelines for staging, treatment, and follow-up. Patients with extragonadal primary tumor or previous treatment for contralateral testicular tumor were excluded. The basic strategy was to individualize treatment according to initial tumor marker response.